322 related articles for article (PubMed ID: 27956204)
1. A new paradigm for drug-induced torsadogenic risk assessment using human iPS cell-derived cardiomyocytes.
Ando H; Yoshinaga T; Yamamoto W; Asakura K; Uda T; Taniguchi T; Ojima A; Shinkyo R; Kikuchi K; Osada T; Hayashi S; Kasai C; Miyamoto N; Tashibu H; Yamazaki D; Sugiyama A; Kanda Y; Sawada K; Sekino Y
J Pharmacol Toxicol Methods; 2017; 84():111-127. PubMed ID: 27956204
[TBL] [Abstract][Full Text] [Related]
2. Proarrhythmia risk prediction using human induced pluripotent stem cell-derived cardiomyocytes.
Yamazaki D; Kitaguchi T; Ishimura M; Taniguchi T; Yamanishi A; Saji D; Takahashi E; Oguchi M; Moriyama Y; Maeda S; Miyamoto K; Morimura K; Ohnaka H; Tashibu H; Sekino Y; Miyamoto N; Kanda Y
J Pharmacol Sci; 2018 Apr; 136(4):249-256. PubMed ID: 29555184
[TBL] [Abstract][Full Text] [Related]
3. Proarrhythmia Risk Assessment in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Using the Maestro MEA Platform.
Qu Y; Vargas HM
Toxicol Sci; 2015 Sep; 147(1):286-95. PubMed ID: 26117837
[TBL] [Abstract][Full Text] [Related]
4. Development of torsadogenic risk assessment using human induced pluripotent stem cell-derived cardiomyocytes: Japan iPS Cardiac Safety Assessment (JiCSA) update.
Kanda Y; Yamazaki D; Osada T; Yoshinaga T; Sawada K
J Pharmacol Sci; 2018 Dec; 138(4):233-239. PubMed ID: 30415824
[TBL] [Abstract][Full Text] [Related]
5. Electrophysiological Characteristics of Human iPSC-Derived Cardiomyocytes for the Assessment of Drug-Induced Proarrhythmic Potential.
Yamamoto W; Asakura K; Ando H; Taniguchi T; Ojima A; Uda T; Osada T; Hayashi S; Kasai C; Miyamoto N; Tashibu H; Yoshinaga T; Yamazaki D; Sugiyama A; Kanda Y; Sawada K; Sekino Y
PLoS One; 2016; 11(12):e0167348. PubMed ID: 27923051
[TBL] [Abstract][Full Text] [Related]
6. CSAHi study: Detection of drug-induced ion channel/receptor responses, QT prolongation, and arrhythmia using multi-electrode arrays in combination with human induced pluripotent stem cell-derived cardiomyocytes.
Kitaguchi T; Moriyama Y; Taniguchi T; Maeda S; Ando H; Uda T; Otabe K; Oguchi M; Shimizu S; Saito H; Toratani A; Asayama M; Yamamoto W; Matsumoto E; Saji D; Ohnaka H; Miyamoto N
J Pharmacol Toxicol Methods; 2017; 85():73-81. PubMed ID: 28163191
[TBL] [Abstract][Full Text] [Related]
7. Availability of human induced pluripotent stem cell-derived cardiomyocytes in assessment of drug potential for QT prolongation.
Nozaki Y; Honda Y; Tsujimoto S; Watanabe H; Kunimatsu T; Funabashi H
Toxicol Appl Pharmacol; 2014 Jul; 278(1):72-7. PubMed ID: 24742750
[TBL] [Abstract][Full Text] [Related]
8. CSAHi study: Validation of multi-electrode array systems (MEA60/2100) for prediction of drug-induced proarrhythmia using human iPS cell-derived cardiomyocytes -assessment of inter-facility and cells lot-to-lot-variability.
Nozaki Y; Honda Y; Watanabe H; Saiki S; Koyabu K; Itoh T; Nagasawa C; Nakamori C; Nakayama C; Iwasaki H; Suzuki S; Washio I; Takahashi E; Miyamoto K; Yamanishi A; Endo H; Shinozaki J; Nogawa H; Kunimatsu T
Regul Toxicol Pharmacol; 2016 Jun; 77():75-86. PubMed ID: 26884090
[TBL] [Abstract][Full Text] [Related]
9. Sex-Related Differences in Drug-Induced QT Prolongation and Torsades de Pointes: A New Model System with Human iPSC-CMs.
Huo J; Wei F; Cai C; Lyn-Cook B; Pang L
Toxicol Sci; 2019 Feb; 167(2):360-374. PubMed ID: 30247688
[TBL] [Abstract][Full Text] [Related]
10. Safety pharmacology studies using EFP and impedance.
Obergrussberger A; Juhasz K; Thomas U; Stölzle-Feix S; Becker N; Dörr L; Beckler M; Bot C; George M; Fertig N
J Pharmacol Toxicol Methods; 2016; 81():223-32. PubMed ID: 27084108
[TBL] [Abstract][Full Text] [Related]
11. Multi-parametric assessment of cardiomyocyte excitation-contraction coupling using impedance and field potential recording: A tool for cardiac safety assessment.
Zhang X; Guo L; Zeng H; White SL; Furniss M; Balasubramanian B; Lis E; Lagrutta A; Sannajust F; Zhao LL; Xi B; Wang X; Davis M; Abassi YA
J Pharmacol Toxicol Methods; 2016; 81():201-16. PubMed ID: 27282640
[TBL] [Abstract][Full Text] [Related]
12. Cardiotoxicity Assessment of Drugs Using Human iPS Cell-Derived Cardiomyocytes: Toward Proarrhythmic Risk and Cardio-Oncology.
Satsuka A; Kanda Y
Curr Pharm Biotechnol; 2020; 21(9):765-772. PubMed ID: 31264543
[TBL] [Abstract][Full Text] [Related]
13. The assessment of electrophysiological activity in human-induced pluripotent stem cell-derived cardiomyocytes exposed to dimethyl sulfoxide and ethanol by manual patch clamp and multi-electrode array system.
Hyun SW; Kim BR; Hyun SA; Seo JW
J Pharmacol Toxicol Methods; 2017 Sep; 87():93-98. PubMed ID: 28377112
[TBL] [Abstract][Full Text] [Related]
14. CSAHi study: Evaluation of multi-electrode array in combination with human iPS cell-derived cardiomyocytes to predict drug-induced QT prolongation and arrhythmia--effects of 7 reference compounds at 10 facilities.
Kitaguchi T; Moriyama Y; Taniguchi T; Ojima A; Ando H; Uda T; Otabe K; Oguchi M; Shimizu S; Saito H; Morita M; Toratani A; Asayama M; Yamamoto W; Matsumoto E; Saji D; Ohnaka H; Tanaka K; Washio I; Miyamoto N
J Pharmacol Toxicol Methods; 2016; 78():93-102. PubMed ID: 26657830
[TBL] [Abstract][Full Text] [Related]
15. Application of optical action potentials in human induced pluripotent stem cells-derived cardiomyocytes to predict drug-induced cardiac arrhythmias.
Lu HR; Hortigon-Vinagre MP; Zamora V; Kopljar I; De Bondt A; Gallacher DJ; Smith G
J Pharmacol Toxicol Methods; 2017 Sep; 87():53-67. PubMed ID: 28501647
[TBL] [Abstract][Full Text] [Related]
16. Detection of Drug-Induced Torsades de Pointes Arrhythmia Mechanisms Using hiPSC-CM Syncytial Monolayers in a High-Throughput Screening Voltage Sensitive Dye Assay.
da Rocha AM; Creech J; Thonn E; Mironov S; Herron TJ
Toxicol Sci; 2020 Feb; 173(2):402-415. PubMed ID: 31764978
[TBL] [Abstract][Full Text] [Related]
17. Electrophysiological characteristics and pharmacological sensitivity of two lines of human induced pluripotent stem cell derived cardiomyocytes coming from two different suppliers.
Goineau S; Castagné V
J Pharmacol Toxicol Methods; 2018; 90():58-66. PubMed ID: 29274391
[TBL] [Abstract][Full Text] [Related]
18. Occurrence of early afterdepolarization under healthy or hypertrophic cardiomyopathy conditions in the human ventricular endocardial myocyte: In silico study using 109 torsadogenic or non-torsadogenic compounds.
Christophe B
Toxicol Appl Pharmacol; 2022 Mar; 438():115914. PubMed ID: 35150662
[TBL] [Abstract][Full Text] [Related]
19. Screening drug-induced arrhythmia [corrected] using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays.
Navarrete EG; Liang P; Lan F; Sanchez-Freire V; Simmons C; Gong T; Sharma A; Burridge PW; Patlolla B; Lee AS; Wu H; Beygui RE; Wu SM; Robbins RC; Bers DM; Wu JC
Circulation; 2013 Sep; 128(11 Suppl 1):S3-13. PubMed ID: 24030418
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of nefazodone-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes.
Lee S; Lee HA; Choi SW; Kim SJ; Kim KS
Toxicol Appl Pharmacol; 2016 Apr; 296():42-53. PubMed ID: 26821276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
